

Product Overview

Changchun BCHT Biotechnology Co.

AGENDA

- **Company Profile**
- **Products on the Market**
 - **Varicella Vaccine, Live**
 - **Influenza Vaccine, Live, Nasal, Freeze-dried**
 - **Rabies Vaccine (Vero Cell) for Human Use**
- **Future Products**
 - **Live Attenuated Herpes Zoster Vaccine**
 - **More on research**
- **Contact us**



COMPANY PROFILE



Invested by Changchun High-tech Industries (Group) Inc.(000661.SZ), **Changchun BCHT Biotechnology Co.** (hereinafter refer to as “**BCHT**”) was established in 2004. BCHT dedicates to R&D, manufacture and sales for human use vaccines and possesses 3 campuses, with totally 235 thousand square meters. In recent 3 years, BCHT’s accumulated costs on R&D exceeds 300 million RMB, making its R&D capability rank the leading place in China.



Varicella Vaccine, Live

- *Higher safety* for free of gelatin;
- **36 months** of validity period, the *longest* in the world;
- *Better protection* for higher titer;
- *Two-dosage* of immunization; and
- Two packaging forms: *vial* and *prefilled syringe*.



PRODUCTS ON THE MARKET

Influenza Vaccine, Live, Nasal, Freeze-dried

- The only Chinese product in WHO Global Action Plan for Influenza;
- **Higher medication compliance** owing to nasal spray;
- **Mucosal immunity + Cellular immunity + Humoral immunity**;
- Manufactured with **SPF eggs**;
- **Higher safety** without such preservative and inactivator as thiomersalate and formaldehyde; and
- As **the first vaccine** in China to pass the evaluation of protective indexes of full-course immune effect.



PRODUCTS ON THE MARKET

Rabies Vaccine (Vero Cell) for Human Use

Its manufacture will soon be recommenced by Jilin Maifeng Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of BCHT.

This Rabies Vaccine boasts the following features:

- ***Microcarrier bioreactor technology*** for production;
- ***High potency*** and ***immunogenicity***;
- ***Higher standard*** for internal control than Chinese national standard;
- ***18 months*** of validity; and
- ***Higher safety*** with lower possibility of adverse reactions.



FUTURE PRODUCTS



- The phase III of clinical trial for our **Live Attenuated Herpes Zoster Vaccine** is expected to complete by the end of 2021.
- More on research:
 - HPV (Pentavalent)
 - EV71+CA16, VLP
 - RSV
 - HIV (Preventability, therapeutic)
 - Component Acellular DTP Vaccine
 - Survivin +MUC1



CONTACT US

Email: info@bchtpharm.com

Address: No. 138 Zhuoyue Street, Chaoyang District,
Changchun, Jilin, China

Website: www.bchtpharm.com

Tel: +86(431)87078891

Fax: + 86(431) 85195516



Thank you!
谢谢！

Changchun BCHT Biotechnology Co.